导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.13% | 2850/4773 |
| 近一周 | -3.00% | 3537/5462 |
| 近一月 | -7.52% | 3851/5421 |
| 近一季 | 12.63% | 105/5209 |
| 近半年 | 1.36% | 1057/4920 |
| 近一年 | -16.90% | 3827/4366 |
| 近两年 | 21.58% | 2618/2954 |
| 近三年 | -9.66% | 2026/2253 |
| 成立以来 | 17.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.86% 2935/4961 |
-3.69% 3474/5312 |
- - |
- - |
| 2025 | 9.13% 2880/4813 |
3.83% 1032/3635 |
1.95% 1999/4076 |
20.71% 1932/4524 |
-14.59% 4345/4813 |
| 2024 | -18.13% 2518/3463 |
-14.27% 2515/2808 |
-10.33% 2439/3014 |
18.79% 931/3129 |
-10.34% 2982/3463 |
| 2023 | -11.71% 1420/2656 |
-2.58% 2021/2280 |
-11.16% 2148/2385 |
1.63% 297/2515 |
0.38% 150/2655 |
| 2022 | -27.10% 1455/2207 |
-10.69% 412/1919 |
-5.09% 1865/2016 |
-19.79% 1814/2113 |
7.20% 324/2208 |
| 2021 | -14.40% 1147/1822 |
-4.00% 843/1255 |
14.15% 266/1330 |
-14.15% 1364/1466 |
-9.02% 1593/1822 |
| 2020 | 85.29% 33/1250 |
15.90% 3/1028 |
38.43% 9/1067 |
7.16% 799/1164 |
7.76% 695/1184 |
| 2019 | 53.12% 86/1092 |
34.72% 106/754 |
-2.76% 362/804 |
11.20% 38/850 |
5.10% 749/918 |
| 2018 | -24.39% 323/834 |
- - |
- - |
- - |
-19.83% 664/691 |
| 2017 | 14.83% 251/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富中证生物科技指数(LOF)C VS. 长安沪深300非周期A(740101) |